Sarah Digby, DO
Internal Medicine · Pinellas Park, FLNPI 1417024704
Payments from drug & device makers
Across 398 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$972
- AbbVie$911
- Novo Nordisk$636
- GSK$463
- Lilly USA, LLC$300
- plus $2K from 32 others
What the payments were for
- Food & beverage$7,174100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $1,480 |
| Boehringer Ingelheim | 47 | $972 |
| AbbVie(2 entities) | 43 | $911 |
| Novo Nordisk | 30 | $636 |
| GSK | 26 | $463 |
| Lilly USA, LLC | 23 | $300 |
| Sanofi-aventis U.S. LLC | 15 | $274 |
| Johnson & Johnson | 18 | $239 |
| Amarin Pharma, Inc. | 10 | $207 |
| Abbott | 10 | $192 |
| Merck | 13 | $191 |
| Amgen(2 entities) | 9 | $153 |
| Bayer | 5 | $127 |
| Kowa Pharmaceuticals America, Inc. | 7 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Corcept Therapeutics | 5 | $94 |
| Eisai Inc. | 4 | $90 |
| Astellas Pharma US Inc | 3 | $65 |
| Pfizer | 4 | $60 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Gilead | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 1 | $39 |
| Companion Medical, Inc. | 2 | $39 |
| Insulet Corporation | 2 | $38 |
| IBSA Pharma Inc. | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Almatica Pharma LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$7,193 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $97,860 |
| JardianceEmpagliflozin | 38 | $45,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $35,445 |
| XareltoRivaroxaban | 22 | $32,591 |
| EliquisApixaban | 28 | $31,781 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $22,997 |
| JanuviaSitagliptin Phosphate | 17 | $16,722 |
| FarxigaDapagliflozin Propanediol | 16 | $14,049 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $9,399 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,937 |
| Gabapentin | 112 | $2,817 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,649 |
| SynthroidLevothyroxine Sodium | 30 | $2,191 |
| Atorvastatin Calcium | 238 | $2,061 |
| Losartan Potassium | 205 | $2,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $636 | $97,86080 claims |
| Boehringer IngelheimJardiance | $972 | $45,57538 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,480 | $39,69651 claims |
| GSKTrelegy Ellipta | $463 | $35,44528 claims |
| Johnson & JohnsonXarelto | $239 | $32,59122 claims |
| PfizerEliquis | $60 | $31,78128 claims |
| MerckJanuvia, Janumet | $191 | $26,12129 claims |
| AbbVieSynthroid | $911 | $2,19130 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $1,964230 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $68862 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pinellas Park
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.